VIDA yields 20000000.00% · ABBV yields 3.12%● Live data
📍 VIDA pulled ahead of the other in Year 1
Combined, VIDA + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VIDA + ABBV for your $10,000?
Vidaroo Corporation, a video technology company, engages in licensing an online video platform and performing professional video production activities. It operates and licenses an online video platform under a software-as-a-service model that consists of a series of Web-based applications, a centralized user console, and an application for the management of the platform. The company's video platform is divided into two editions comprising Publisher, which is divided into a series of modules; and Enterprise edition that allows management of multiple content destinations. It licenses its video platform in on-demand and enterprise programs. The company's video platform provides video management, live streaming, content delivery and syndication, player functionality, social destination, analytics, and advertising capabilities. It is also involved in the creation and support of video imagery in the entertainment business; and support of video production for traditional media and corporate presentations, and in-house production of content. The company was formerly known as Gen2Media Corporation and changed its name to Vidaroo Corporation in April 2010. Vidaroo Corporation is based in Winter Garden, Florida.
Full VIDA Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.